S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
DOD Consultant's big 2024 prediction looks to be coming true (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
DOD Consultant's big 2024 prediction looks to be coming true (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
DOD Consultant's big 2024 prediction looks to be coming true (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
DOD Consultant's big 2024 prediction looks to be coming true (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
DOD Consultant's big 2024 prediction looks to be coming true (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
DOD Consultant's big 2024 prediction looks to be coming true (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
DOD Consultant's big 2024 prediction looks to be coming true (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
DOD Consultant's big 2024 prediction looks to be coming true (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
NASDAQ:NUVA

NuVasive (NUVA) Stock Forecast, Price & News

$39.75
0.00 (0.00%)
(As of 09/11/2023)
Compare
Today's Range
$39.75
$39.75
50-Day Range
$38.12
$43.08
52-Week Range
$35.17
$49.53
Volume
N/A
Average Volume
1.16 million shs
Market Capitalization
$2.08 billion
P/E Ratio
79.50
Dividend Yield
N/A
Price Target
$50.75

NuVasive MarketRank™ Forecast

Analyst Rating
Hold
2.18 Rating Score
Upside/​Downside
27.7% Upside
$50.75 Price Target
Short Interest
Healthy
10.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of NuVasive in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
16.67%
From $2.22 to $2.59 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

431st out of 976 stocks

Medical Devices Industry

6th out of 8 stocks


NUVA stock logo

About NuVasive (NASDAQ:NUVA) Stock

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.

NUVA Price History

NUVA Stock News Headlines

The Bio-Tech Stock That Needs Your Attention!
There a Few Opportunities Like This Stock! Sign Up Today And Get Our NExt Bio-Tech Alert!
Globus Subsides on Merger with NuVasive
Globus Medical Completes Merger with NuVasive
The Bio-Tech Stock That Needs Your Attention!
There a Few Opportunities Like This Stock! Sign Up Today And Get Our NExt Bio-Tech Alert!
Truist Financial Remains a Hold on NuVasive (NUVA)
NuVasive Announces Second Quarter 2023 Financial Results
NuVasive Inc NUVA Stock Quote
NuVasive (NUVA) Receives a Hold from Truist Financial
NuVasive (NUVA) Receives a Buy from RBC Capital
NUVA - NuVasive, Inc.
Finalist: Gregory Jackson
See More Headlines
Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Company Calendar

Last Earnings
8/02/2023
Today
9/28/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:NUVA
CUSIP
67070410
Employees
3,000
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$50.75
High Stock Price Forecast
$58.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
+27.7%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
11 Analysts

Profitability

Net Income
$40.41 million
Pretax Margin
3.41%

Debt

Sales & Book Value

Annual Sales
$1.23 billion
Cash Flow
$4.96 per share
Book Value
$17.02 per share

Miscellaneous

Free Float
52,171,000
Market Cap
$2.08 billion
Optionable
Optionable
Beta
1.07

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. J. Christopher BarryMr. J. Christopher Barry (Age 50)
    CEO & Director
    Comp: $3.08M
  • Mr. Matthew K. Harbaugh (Age 53)
    Principal Accounting Officer, CFO & Exec. VP
    Comp: $1.37M
  • Mr. Dale A. Wolf (Age 43)
    Sr. VP of Global Operations
    Comp: $782.6k
  • Mr. Nathaniel B. Sisitsky Esq. (Age 48)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $842.84k
  • Mr. Michael Farrington (Age 39)
    Sr. VP of People & Culture
    Comp: $626.46k
  • Mr. Ryan Donahoe
    Sr. VP & Chief Technology Officer
  • Ms. Juliet C. Cunningham
    VP of Investor Relations
  • Mr. Sean Freeman
    Sr. VP of Strategy & Corp. Devel.
  • Ms. Lisa Pecora
    VP & Head of Global Commercial Fin.
  • Ms. Aviva McPherron
    Sr. VP of Information Technology













NUVA Stock - Frequently Asked Questions

Should I buy or sell NuVasive stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NUVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View NUVA analyst ratings
or view top-rated stocks.

What is NuVasive's stock price forecast for 2023?

11 analysts have issued 12 month target prices for NuVasive's shares. Their NUVA share price forecasts range from $45.00 to $58.00. On average, they predict the company's stock price to reach $50.75 in the next twelve months. This suggests a possible upside of 27.7% from the stock's current price.
View analysts price targets for NUVA
or view top-rated stocks among Wall Street analysts.

How have NUVA shares performed in 2023?

NuVasive's stock was trading at $41.24 at the start of the year. Since then, NUVA stock has decreased by 3.6% and is now trading at $39.75.
View the best growth stocks for 2023 here
.

When is NuVasive's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our NUVA earnings forecast
.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings data on Wednesday, August, 2nd. The medical device company reported $0.56 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.56. The medical device company had revenue of $317.80 million for the quarter, compared to analysts' expectations of $322.53 million. NuVasive had a net margin of 2.32% and a trailing twelve-month return on equity of 12.17%. The business's revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.47 earnings per share.

How will NuVasive's stock buyback program work?

NuVasive declared that its Board of Directors has authorized a share repurchase plan on Tuesday, November 9th 2021, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 3.5% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.27 billion-$1.30 billion, compared to the consensus revenue estimate of $1.29 billion.

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by many different retail and institutional investors. Top institutional shareholders include KRYGER CAPITAL Ltd (4.51%), Alpine Associates Management Inc. (3.31%), Dimensional Fund Advisors LP (2.97%), Paradice Investment Management LLC (2.60%), Westchester Capital Management LLC (2.05%) and Geode Capital Management LLC (2.02%). Insiders that own company stock include James Christopher Barry, Lucas Vitale and Massimo Calafiore.
View institutional ownership trends
.

How do I buy shares of NuVasive?

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $39.75.

How much money does NuVasive make?

NuVasive (NASDAQ:NUVA) has a market capitalization of $2.08 billion and generates $1.23 billion in revenue each year. The medical device company earns $40.41 million in net income (profit) each year or $0.50 on an earnings per share basis.

How many employees does NuVasive have?

The company employs 3,000 workers across the globe.

Does NuVasive have any subsidiaries?
The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.
Read More
How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.

This page (NASDAQ:NUVA) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -